




27 June 2016

Daily news and comments on the Life Sciences Sector in **Australia** by The Daily Molecule, part of Van Leeuwenhoek Institute

Companies in Today's newsletter:

- CELLMID (CDY.AX)
- IMMURON (IMX.AX, OTCQB: IMROY)



| | 24 June 2016 | 1 mth | 3 mth | 1yr | YTD |
|----------------------|--------------|-------|-------|--------|--------|
| ASX All Ordinaries | 5,192.80 | -4.5% | 2.3% | -6.2% | -2.8% |
| Nasdaq Biotech Index | 2,605.00 | -9.5% | -1.2% | -33.2% | -26.4% |
| Nasdaq Index | 4,285.70 | -3.8% | -1.2% | -7.3% | -6.0% |
| Dow Jones Index | 17,400.75 | -2.5% | -0.8% | -3.0% | -0.1% |
| Euro STOXX 50 | 2,776.09 | -9.3% | -7.6% | -23.3% | -12.6% |



CELLMID (ASX: CDY)

PRICE: AUD 0.02 (-0.0%)

Cellmid announced that it has completed the first ever study showing that treatment with a midkine (MK) antibody accelerated bone fracture healing in an aged rodent model of the condition. The study was led by Dr Astrid Liedert at the Institute of Orthopedic Research and Biomechanics, University Medical Center Ulm, Germany and the results were recently published in the British Journal of Pharmacology. Demonstrating the beneficial effects of a MK antibody in bone fracture healing has considerable clinical significance. The rate of delayed bone healing and even nonunion formation can be as high as 10% of all long bone fractures. The incidence of bone complications following fractures increases markedly amongst the older population. The data generated adds substantial commercial value to Cellmid's antibody assets and the new intellectual property is now the subject of a patent application by the Company. Commercialisation of Cellmid's MK antibody assets are carried out by wholly owned subsidiary Lyramid, a company dedicated to developing drugs in various conditions by targeting MK. Cellmid is leader in MK intellectual property with a patent portfolio that currently includes 82 patents in 21 patent families, covering the use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders. MK is a multifunctional growth factor that is highly expressed during embryonic development. It is barely detectable in healthy adults but it is highly expressed in cancer, inflammation and auto immune diseases. MK is a growth factor with several important biological functions. It contributes to cell growth and differentiation, enhances the survival and migration of target cells. MK expression peaks around mid-gestation, and plays an important role in neurogenesis. However, MK is downregulated by the time of birth and MK expression in adult tissue is generally weak or undetectable. **Based on our risk adjusted NPV based valuation, we believe that Cellmid is clearly undervalued at the current share price of AUD 0.02. Using our valuation model, the Company's current total value is AUD 80 million, or AUD 0.086 per share.**

IMMURON (ASX: IMC)

PRICE: AUD 0.255 (-5.6%)

Immuron announced that it has entered into a distribution agreement with QBID, one of the leaders in Australia-China e-commerce. Both Travelan and Protectyn will be covered by the marketing/distribution agreement, with products to be made available on the sales platform from 1 June. The agreement provides for an exclusivity period of 2 years based on QBID achieving target sales volumes. QBID is an official Australian partner of JD.com for products sourced from Australia and New Zealand. JD.com is China's largest online direct sales company and offers a turnkey e-commerce platform for Australian product entry into China. Travelan, Immuron's natural product for the prevention of traveller's diarrhea, holds direct relevance to the increasingly mobile Chinese population. In 2015, more than 104 million Chinese traveled outside



of China. The company also announced last week that its lead compound IMM-124E Phase II clinical trial for the treatment of NASH (Non-Alcoholic Steatohepatitis) has successfully reached its 50% recruitment milestone with 56 patients having been successfully randomised and an additional 4 patients to be randomised this week. To date, 25 patients have successfully completed treatment. No significant treatment adverse events have been reported. In December 2014, the Company announced the launch of the NASH Phase II multinational multicenter randomised double blind placebo controlled study of its proprietary compound IMM-124E for the treatment of NASH, with the first patient randomised in February 2016. Immuron now has a total of 28 active clinical study sites across the USA, Australia and Israel, including 4 additional sites initiated since January. At the moment we do not have active coverage yet on Immuron.

The Daily Molecule is a publication of Van Leeuwenhoek Institute Inc

Marcel Wijma MSc
CEO & Managing Director

Van Leeuwenhoek Research (US) Inc
244 Fifth Avenue, Suite W204
New York, NY, 10001 USA

Phone US: +1 917 460 6185
Phone NL: +31 684 892 954

m.wijma@leeuwenhoek.com
www.leeuwenhoek.com

THE DAILY MOLECULE

YOUR EYES AND EARS ON THE GLOBAL BIOTECH MARKET

| Company | Ticker | Price | Perf 1mth | Perf YTD | Perf 1 yr | Market cap |
|------------------------|--------|-------|-----------|----------|-----------|------------|
| ACRUX | ACR.AX | 0.705 | 5.3% | -9.2% | -19.2% | 117.38 |
| ACTINOGEN | ACW.AX | 0.071 | -15.6% | 32.8% | 2.5% | 34.94 |
| ADHERIUM | ADR.AX | 0.490 | 6.3% | -19.7% | -15.0% | 70.51 |
| ADMEDUS | AHZ.AX | 0.285 | -8.7% | -54.0% | -52.3% | 411.11 |
| ANTEO DIAGNOSTICS | ADO.AX | 0.040 | 4.7% | -41.6% | -43.9% | 33.79 |
| ANTISENSE | ANP.AX | 0.031 | -40.7% | -50.7% | -69.6% | 5.01 |
| AVITA MEDICAL | AVH.AX | 0.091 | -8.0% | 23.7% | 47.4% | 29.60 |
| BENITEC | BLT.AX | 0.092 | -17.3% | -69.2% | -88.4% | 10.64 |
| BIOTRON | BIT.AX | 0.057 | 1.6% | 26.0% | -58.0% | 13.82 |
| BIONOMICS | BNO.AX | 0.300 | -3.3% | -20.3% | -35.9% | 125.25 |
| CELLMID | CDY.AX | 0.030 | 42.9% | 25.0% | 15.4% | 23.78 |
| CLINUVEL | CUV.AX | 4.290 | -2.3% | 61.6% | 39.8% | 191.33 |
| CYNATA | CYP.AX | 0.285 | -14.1% | -14.1% | -66.5% | 17.56 |
| ELLEX MEDICAL LASERS | ELX.AX | 0.970 | 28.8% | 40.0% | 218.2% | 111.16 |
| FACTOR THERAPEUTICS | FTT.AX | 0.036 | 0.0% | -8.1% | -8.3% | 9.48 |
| IDT AUSTRALIA | IDT.AX | 0.245 | -9.8% | -25.7% | 19.6% | 46.84 |
| IMMURON | IMC.AX | 0.255 | -26.2% | -49.6% | 12.4% | 19.33 |
| IMPEDIMED | IPD.AX | 0.930 | 10.2% | -17.8% | 13.5% | 272.58 |
| IMUGENE | IMU.AX | 0.008 | 0.0% | -16.7% | -9.1% | 10.64 |
| INVION GROUP | IVX.AX | 0.005 | 20.0% | 0.0% | -68.4% | 4.11 |
| LBT INNOVATIONS | LBT.AX | 0.170 | 5.9% | 80.0% | 205.1% | 19.55 |
| MEDLAB CLINICAL | MDC.AX | 0.390 | 81.1% | 152.6% | 140.0% | 62.71 |
| MESOBLAST | MSB.AX | 1.055 | -33.1% | -32.7% | -68.7% | 334.54 |
| NEUREN PHARM. | NEU.AX | 0.056 | -26.0% | -53.0% | -30.8% | 91.01 |
| NOVOGEN | NRT.AX | 0.098 | -7.0% | -7.0% | -57.2% | 41.55 |
| ONCOSIL | OSL.AX | 0.120 | 3.9% | -46.0% | 22.7% | 42.64 |
| OPTHEA | OPT.AX | 0.455 | -1.0% | 20.0% | 20.0% | 67.39 |
| ORTHOCELL | OCC.AX | 0.280 | -23.2% | -18.2% | 1.6% | 23.10 |
| OSPREY MEDICAL | OSP.AX | 0.205 | -10.0% | -25.0% | -64.0% | 25.26 |
| PARADIGM BIOPHARMA | PAR.AX | 0.345 | 16.7% | 16.7% | -5.4% | 30.22 |
| PHARMAXIS | PXS.AX | 0.260 | 0.0% | -27.8% | 13.0% | 81.34 |
| PHOSPHAGENICS | POH.AX | 0.013 | -36.4% | 16.7% | -36.4% | 16.41 |
| PHYLOGICA | PYC.AX | 0.014 | -22.2% | 7.7% | -20.0% | 14.03 |
| PRIMA BIOMED | PRR.AX | 0.043 | -2.2% | -13.7% | -38.9% | 92.70 |
| PRANA BIOTECH | PBT.AX | 0.098 | 21.3% | -9.4% | -42.9% | 47.91 |
| PRESCIENT THERAPEUTICS | PTX.AX | 0.085 | -17.0% | -4.9% | 36.2% | 4.48 |
| PSIVIDA | PVA.AX | 4.080 | 18.4% | -29.1% | -5.3% | 119.95 |
| RECCE | RCE.AX | 0.240 | 51.4% | -11.7% | -11.7% | 17.45 |
| REGENEUS | RGS.AX | 0.150 | -6.1% | 64.9% | -22.5% | 30.09 |
| RESMED | RMD.AX | 8.300 | 1.5% | 8.3% | 8.5% | 11703.00 |
| RHINOMED | RNO.AX | 0.017 | -13.0% | -25.9% | -42.9% | 9.17 |
| SIMAVITA | SVA.AX | 0.050 | 19.4% | -73.1% | -91.9% | 4.61 |
| SOMNOMED | SOM.AX | 3.220 | 9.6% | 25.1% | 33.1% | 164.03 |
| STAR PHARMA | SPL.AX | 0.650 | 0.0% | -4.0% | -8.3% | 207.42 |
| SUDA | SUD.AX | 0.020 | -14.8% | -14.8% | -11.5% | 19.68 |
| UNIVERSAL BIOSENSORS | UBI.AX | 0.295 | -7.1% | -42.2% | -16.1% | 51.89 |
| VIRALYTICS | VLA.AX | 0.960 | 30.3% | 59.9% | 48.6% | 176.64 |

Source: Van Leeuwenhoeck Institute Inc



Disclaimer

The facts stated and the opinion and prognoses given in this publication are based on data and information considered to be reliable and have been carefully worked into our analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness. Van Leeuwenhoek Institute. does not accept responsibility or liability in any way in respect to the information stated herein.

Van Leeuwenhoek Institute does not hold or have positions in securities as referred to in this publication. The views expressed in this publication accurately reflect the analyst's personal views on the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Van Leeuwenhoek Institute is in any way related to the specific recommendations or views contained in this publication.

Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. The value of, or income from, any investments referred to herein may fluctuate and/or be affected by changes in exchange rates. Past performances are not indicative for future results. Investors should make their own investment decisions without relying on this publication.

Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuer or market discussed herein and other persons should not take any action on the basis of this publication.

Information, opinions or recommendations contained in this publication are submitted solely for advisory and information purposes. The information used and statements of fact made, have been obtained from sources considered reliable, but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This publication is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed.

Van Leeuwenhoek Institute does not accept any equity compensation. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence.

*Periodic Research reports and research notes on this Company are available at our web site:
www.leeuwenhoek.com*

© Copyright 2016 by Van Leeuwenhoek Institute Inc.